Since FFAs have long been recognized as important regulators of glucose homeostasis via their ability to stimulate insulin secretion in the presence of glucose, FFAR1 became a promising therapeutic target for type 2 diabetes treatment since its deorphanization, and a number of small-molecule FFAR1 agonists are under development as drugs for type 2 diabetes (Ghislain and Poitot, 2016; Hara, 2016; Kimura et al., 2020). The gene discussed is INS; the disease is type 2 diabetes mellitus.